Algorithmic Biologics, a deeptech molecular computing platform company, announced the appointment of Hiranjith GH as Chief Business Officer (CBO) to lead the company’s commercial operations and its expansion globally, primarily in the US.
With decades of experience in the pharmaceutical and life sciences industries, Hiran brings valuable experience and expertise in go-to-market strategy for the US, business development, solution development, and cross-border team leadership.
Based in the San Francisco Bay Area, Hiran most recently served as the Vice President and Site Head for MedGenome USA, launching and scaling its commercial operations in the US. Prior to that, he held various corporate leadership and business roles at MedGenome since its incorporation as an independent entity.
He previously led teams at Novartis, ZS Associates and Accenture Management Consulting advising internal and external commercialization teams on marketing analytics, brand planning and commercial operations primarily in the Life Sciences and Pharmaceuticals sectors.
“We are thrilled to welcome Hiran to the Algorithmic Biologics team. His proven track record of scaling businesses, building global teams and forging strategic partnerships aligns perfectly with our mission. We are confident that Hiran’s leadership will be instrumental as we continue to expand our global footprint and deliver innovative solutions to our partners and customers,” said Manoj Gopalkrishnan, Founder & CEO of Algorithmic Biologics.
“I am excited to join Algorithmic Biologics at this pivotal moment. The company’s innovative molecular computing technology has the potential to transform not just healthcare but also agriculture, animal science, and large-scale population screening. I look forward to working with the talented team here to accelerate growth, drive innovation, and expand our impact across diverse industries,” said Hiranjith GH, Chief Business Officer at Algorithmic Biologics.
Algorithmic Biologics use molecular computing to revolutionize molecular testing—enabling faster, more cost-effective, and highly accurate molecular testing by embedding AI directly into the test tube.
